Market Position REVA Medical specializes in bioresorbable polymer vascular devices, offering Fantom Encore as a drug-eluting scaffold. This positions the company to target interventional cardiology centers seeking next‑gen stent solutions that restore natural artery function after healing, presenting opportunities to expand adoption in hospitals and catheterization labs.

Clinical Momentum With a Series B financing of 45 million and ongoing MOTIV scaffold clinical program, there is investor and clinical validation signaling growth potential. Leverage this to engage procurement and clinical teams highlighting funding-backed expansion and pipeline progress.

Expansion Signals Launch of Fantom Encore in 2018 and active post‑market and clinical trials suggest readiness to scale adoption. Focus sales outreach on centers pursuing innovative BRS options and surgeons/interventionalists seeking durable, resorbable alternatives to metallic stents.

Financial Levers Revenue range indicates a small‑to‑mid scale operation with growth trajectory. Approach finance and market access teams with value propositions around total cost of ownership, potential reduced reinterventions, and favorable long‑term vessel healing outcomes.

Strategic Partnerships Relatively lean employee base and partnerships with multinational players (as indicated by comparables) imply opportunity to pursue distribution or co‑development agreements with larger medical device networks to accelerate market reach and regulatory progression.